BIOMAT Database Logo BIOMAT Database Logo

ROCK inhibitors 3: Design, synthesis and structure-activity relationships of 7-azaindole-based Rho kinase (ROCK) inhibitors. 2018

Upul K Bandarage, and Jingrong Cao, and Jon H Come, and John J Court, and Huai Gao, and Marc D Jacobs, and Craig Marhefka, and Suganthi Nanthakumar, and Jeremy Green
Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210, USA. Electronic address: upul_bandarage@vrtx.com.

Rho kinase (ROCK) inhibitors are potential therapeutic agents for the treatment of a variety of disorders including hypertension, glaucoma and erectile dysfunction. Here we disclose a series of potent and selective ROCK inhibitors based on a substituted 7-azaindole scaffold. Substitution of the 3-position of 7-azaindole led to compounds such as 37, which possess excellent ROCK inhibitory potency and high selectivity against the closely related kinase PKA.

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D012995 Solubility The ability of a substance to be dissolved, i.e. to form a solution with another substance. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Solubilities
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D047428 Protein Kinase Inhibitors Agents that inhibit PROTEIN KINASES. Protein Kinase Inhibitor,Inhibitor, Protein Kinase,Inhibitors, Protein Kinase,Kinase Inhibitor, Protein,Kinase Inhibitors, Protein
D054460 rho-Associated Kinases A group of intracellular-signaling serine threonine kinases that bind to RHO GTP-BINDING PROTEINS. They were originally found to mediate the effects of rhoA GTP-BINDING PROTEIN on the formation of STRESS FIBERS and FOCAL ADHESIONS. Rho-associated kinases have specificity for a variety of substrates including MYOSIN-LIGHT-CHAIN PHOSPHATASE and LIM KINASES. rho-Associated Kinase,ROCK Protein Kinases,ROCK-I Protein Kinase,ROCK-II Protein Kinase,ROK Kinase,p160 rhoA-Binding Kinase ROKalpha,p160ROCK,rho-Associated Coiled-Coil Containing Protein Kinase 1,rho-Associated Coiled-Coil Containing Protein Kinase 2,rho-Associated Coiled-Coil Kinase,rho-Associated Kinase 1,rho-Associated Kinase 2,rho-Associated Kinase alpha,rho-Associated Kinase beta,rho-Associated Protein Kinase alpha,rho-Associated Protein Kinase beta,rho-Kinase,Coiled-Coil Kinase, rho-Associated,Protein Kinases, ROCK,ROCK I Protein Kinase,ROCK II Protein Kinase,p160 rhoA Binding Kinase ROKalpha,rho Associated Coiled Coil Containing Protein Kinase 1,rho Associated Coiled Coil Containing Protein Kinase 2,rho Associated Coiled Coil Kinase,rho Associated Kinase,rho Associated Kinase 1,rho Associated Kinase 2,rho Associated Kinase alpha,rho Associated Kinase beta,rho Associated Kinases,rho Associated Protein Kinase alpha,rho Associated Protein Kinase beta,rho Kinase
D018360 Crystallography, X-Ray The study of crystal structure using X-RAY DIFFRACTION techniques. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) X-Ray Crystallography,Crystallography, X Ray,Crystallography, Xray,X Ray Crystallography,Xray Crystallography,Crystallographies, X Ray,X Ray Crystallographies

Related Publications

Upul K Bandarage, and Jingrong Cao, and Jon H Come, and John J Court, and Huai Gao, and Marc D Jacobs, and Craig Marhefka, and Suganthi Nanthakumar, and Jeremy Green
ROCK inhibitors 4: Structure-activity relationship studies of 7-azaindole-based rho kinase (ROCK) inhibitors.
February 2021, Bioorganic & medicinal chemistry letters,
Upul K Bandarage, and Jingrong Cao, and Jon H Come, and John J Court, and Huai Gao, and Marc D Jacobs, and Craig Marhefka, and Suganthi Nanthakumar, and Jeremy Green
Design and synthesis of potent and selective azaindole-based Rho kinase (ROCK) inhibitors.
December 2008, ChemMedChem,
Upul K Bandarage, and Jingrong Cao, and Jon H Come, and John J Court, and Huai Gao, and Marc D Jacobs, and Craig Marhefka, and Suganthi Nanthakumar, and Jeremy Green
Design, synthesis, anticonvulsant activity and structure-activity relationships of novel 7-Azaindole derivatives.
April 2023, Bioorganic chemistry,
Upul K Bandarage, and Jingrong Cao, and Jon H Come, and John J Court, and Huai Gao, and Marc D Jacobs, and Craig Marhefka, and Suganthi Nanthakumar, and Jeremy Green
Design, synthesis and structure-activity relationships of novel biarylamine-based Met kinase inhibitors.
May 2010, Bioorganic & medicinal chemistry letters,
Upul K Bandarage, and Jingrong Cao, and Jon H Come, and John J Court, and Huai Gao, and Marc D Jacobs, and Craig Marhefka, and Suganthi Nanthakumar, and Jeremy Green
Rho kinase (ROCK) inhibitors.
July 2007, Journal of cardiovascular pharmacology,
Upul K Bandarage, and Jingrong Cao, and Jon H Come, and John J Court, and Huai Gao, and Marc D Jacobs, and Craig Marhefka, and Suganthi Nanthakumar, and Jeremy Green
Design, synthesis, and structure-activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors.
April 2005, Bioorganic & medicinal chemistry letters,
Upul K Bandarage, and Jingrong Cao, and Jon H Come, and John J Court, and Huai Gao, and Marc D Jacobs, and Craig Marhefka, and Suganthi Nanthakumar, and Jeremy Green
Design, synthesis and structure-activity relationships of benzoxazinone-based factor Xa inhibitors.
February 2003, Bioorganic & medicinal chemistry letters,
Upul K Bandarage, and Jingrong Cao, and Jon H Come, and John J Court, and Huai Gao, and Marc D Jacobs, and Craig Marhefka, and Suganthi Nanthakumar, and Jeremy Green
Design and synthesis of Rho kinase inhibitors (II).
January 2007, Bioorganic & medicinal chemistry,
Upul K Bandarage, and Jingrong Cao, and Jon H Come, and John J Court, and Huai Gao, and Marc D Jacobs, and Craig Marhefka, and Suganthi Nanthakumar, and Jeremy Green
Design and synthesis of Rho kinase inhibitors (I).
May 2004, Bioorganic & medicinal chemistry,
Upul K Bandarage, and Jingrong Cao, and Jon H Come, and John J Court, and Huai Gao, and Marc D Jacobs, and Craig Marhefka, and Suganthi Nanthakumar, and Jeremy Green
Design and synthesis of rho kinase inhibitors (III).
January 2007, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!